March 23, 2022
Aptose Reports Results for the Fourth Quarter and Full Year 2021
– HM43239 clinical remission at 120mg expands list of potential treatable AML populations – – On track to initiate genotype-enriched…
Pharmaceuticals, Biotechnology and Life Sciences
– HM43239 clinical remission at 120mg expands list of potential treatable AML populations – – On track to initiate genotype-enriched…
CONSOLIDATED FIGURES AS OF DECEMBER 31in millions of € 20212020 adjusted 62021/2020 Change Revenue1,064.0934.2+13.9% Change at constant exchange rates +14.9% Change at constant exchange rates and…
ZÜRICH, Switzerland, March 22, 2022 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by CDR-Life, please note that…
GUANGZHOU, China, March 21, 2022 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a…
MELBOURNE, Australia and BRUSSELS, Belgium, March 22, 2022 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is…
MALVERN, Pa., March 21, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and…
Orphazyme A/SCompany announcementNo. 12/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 21, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the…
FORT COLLINS, Colo., March 21, 2022 (GLOBE NEWSWIRE) — Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a…
BILLERICA, Mass., March 21, 2022 (GLOBE NEWSWIRE) — SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company…
Company to undergo a strategic portfolio review while continuing to execute on the development of its three wholly-owned clinical stage…